证券代码：300957 证券简称：贝泰妮 云南贝泰妮生物科技集团股份有限公司 投资者关系活动记录表 编号：2023-004 投资者 关系活 □特定对象调研 □分析师会议 动类别 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 通过全景网(http://ir.p5w.net)参与 2023 年云南辖区上 市公司投资者集体接待日的投资者 时间 2023 年 5 月 11 日 10:30-12:00 地点 线上会议 上市公 司接待 副总经理、董事会秘书、财务总监：王龙 人员姓名 证券事务代表：许玲 Q：请问贵公司怎么样才能提高产品的知名度？ A：尊敬的投资者您好！公司建立了高效的营销矩阵，全链路 高效营销。除了线上多平台的营销，线下方面，公司积极开 展专业学术活动以及其他线下推广活动，譬如 4 月举办的敏 投资者 关系活 感肌高峰论坛。从各个方面提高宣传力度，提升公司品牌的 动主要 内容介 认知度。谢谢您的关注！ 绍 Q：贝泰妮的主要客户群体是哪些人群？ A：尊敬的投资者，您好！公司主品牌聚焦敏感肌+泛敏感肌 人群；其他品牌方面，薇诺娜宝贝专注婴童护肤，瑷科缦专 注抗老高端科技， ...

证券代码：300957 证券简称：贝泰妮 公告编号：2023-028 云南贝泰妮生物科技集团股份有限公司 关于参加云南辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，云南贝泰妮生物科技集团股份有限公司 （以下简称"公司"）将参加由云南证监局、云南省上市公司协会与深圳市全景 网络有限公司联合举办的"2022 年度云南辖区上市公司投资者网上集体接待日 暨集体业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 5 月 11 日（周四）10:30-12:00。届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告！ 云南贝泰妮生物科技集团股份有限公司董事会 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 863,307,083.80, representing a 6.78% increase compared to CNY 808,520,247.30 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2023 was CNY 158,265,044.32, an increase of 8.41% from CNY 145,983,362.57 in the previous year[3]. - Basic earnings per share for Q1 2023 was CNY 0.37, up 8.82% from CNY 0.34 in the previous year[3]. - Operating profit for Q1 2023 was CNY 180,180,592.57, slightly up from CNY 175,602,958.53 in Q1 2022, showing a growth of 3.3%[24]. - The total comprehensive income for Q1 2023 was CNY 155,015,286.18, compared to CNY 145,416,665.70 in the same period last year, reflecting an increase of 6.5%[24]. Cash Flow - The net cash flow from operating activities was negative CNY 196,770,597.63, a decline of 17.70% compared to negative CNY 167,176,118.31 in the same period last year[3]. - Cash received from operating activities in Q1 2023 was RMB 10.22 million, a decrease of RMB 9.76 million or approximately 48.84% year-on-year, mainly due to reduced government rewards[13]. - Cash recovered from investments in Q1 2023 was RMB 1,049.62 million, a decrease of RMB 1,085.53 million or approximately 50.84% year-on-year, due to fewer redeemed entrusted financial products[14]. - The cash inflow from operating activities amounted to CNY 956,511,167.50, an increase from CNY 902,621,356.45 in the previous period, representing a growth of approximately 5.9%[26]. - The net increase in cash and cash equivalents was CNY -835,818,274.37, compared to CNY -470,413,700.13 in the previous period, indicating a significant decline[27]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 6,451,518,702.11, a decrease of 3.98% from CNY 6,718,716,893.90 at the end of the previous year[3]. - Total liabilities decreased to CNY 695,217,759.77 from CNY 1,116,941,237.73, indicating a reduction of approximately 37.8%[21]. - The company's total equity increased to CNY 5,756,300,942.34 from CNY 5,601,775,656.17, reflecting a growth of 2.8%[21]. - The total current assets decreased from RMB 5,715,032,617.35 to RMB 5,378,838,491.62, reflecting a decline of approximately 5.9%[19]. - The company's cash and cash equivalents decreased by 36.17% to CNY 1,604,874,427.05 from CNY 2,514,295,715.26 at the beginning of the year[7]. Expenses and Impairments - The company's financial expenses (net) for Q1 2023 were negative CNY 6,835,097.24, a 90.03% increase in expenses compared to negative CNY 3,596,862.21 in the previous year[10]. - Research and development expenses increased to CNY 33,955,217.71 from CNY 30,996,691.98, marking an increase of 6.4%[22]. - The total cost of operations rose to CNY 718,760,135.76, compared to CNY 663,419,657.64 in the previous year, an increase of 8.3%[22]. - Credit impairment losses in Q1 2023 were RMB 2.74 million, an increase of RMB 5.71 million or approximately 192.31% year-on-year, due to net provisions for receivables impairment[11]. - Asset impairment losses in Q1 2023 amounted to RMB 4.31 million, an increase of RMB 7.36 million or approximately 241.66% year-on-year, mainly due to net provisions for inventory impairment[11]. Investment Income - Investment income for Q1 2023 was CNY 5,688,720.31, a decrease of 73.62% from CNY 21,560,870.17 in the same period last year[10]. - The company reported a significant increase of 1,581.50% in fair value changes, amounting to CNY 31,451,953.37 compared to CNY 1,870,466.34 in the previous year[10]. - In Q1 2023, investment income was RMB 5.69 million, a decrease of RMB 15.87 million or approximately 73.62% year-on-year, mainly due to fewer redeemed entrusted financial products[11]. - Fair value changes in Q1 2023 resulted in a gain of RMB 31.45 million, an increase of RMB 29.58 million year-on-year, primarily from the fair value changes of held trading financial assets[11]. - The company reported a cash inflow of CNY 10,059,178.94 from investment income, which decreased from CNY 22,610,436.58 in the previous period, representing a decline of approximately 55.6%[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,544[15]. - The company reported a cash dividend of RMB 8.00 per 10 shares, totaling an estimated cash distribution of RMB 338,880,000 based on a total share capital of 423,600,000 shares[17]. - The company plans to implement a 2023 restricted stock incentive plan to attract and retain talent, pending shareholder approval[17].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15% compared to 2021[8]. - The net profit attributable to shareholders for 2022 was RMB 300 million, which is a 10% increase from the previous year[8]. - The company's operating revenue for 2022 was ¥5,013,873,729.44, representing a 24.65% increase compared to ¥4,022,403,431.75 in 2021[14]. - The net profit attributable to shareholders for 2022 was ¥1,051,228,828.98, up 21.82% from ¥862,922,946.61 in 2021[14]. - The net profit after deducting non-recurring gains and losses was ¥951,225,441.18, reflecting a 17.00% increase from ¥813,020,602.86 in 2021[14]. - The company's cash flow from operating activities decreased by 33.25% to ¥769,445,621.45 from ¥1,152,720,351.41 in 2021[14]. - The total assets at the end of 2022 were ¥6,718,716,893.90, a 15.59% increase from ¥5,812,491,217.77 at the end of 2021[14]. - The net assets attributable to shareholders increased by 16.76% to ¥5,552,272,818.71 from ¥4,755,204,197.34 at the end of 2021[14]. - The company's basic earnings per share for 2022 were ¥2.48, an increase of 16.98% from ¥2.12 in 2021[14]. - The gross profit margin was approximately 75.21%, showing a slight decrease of 0.80 percentage points year-on-year, while the net profit margin remained stable at about 20.97%[48]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[8]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[8]. - The company aims to leverage internet and AI technologies to enhance its retail system and achieve deep consumer engagement[23]. - The company is positioned as a leading player in the health and wellness sector in China, capitalizing on the rapid growth of the cosmetics industry[23]. - The company plans to open two new manufacturing facilities in 2023, aiming to increase production capacity by 40%[146]. - The company will expand its offline sales channels, including OTC pharmacies and hospitals, to increase brand exposure and reach end consumers more effectively[112]. Research and Development - The company has invested RMB 50 million in R&D for new technologies aimed at enhancing product efficacy and safety[8]. - The company has invested in establishing research centers in Kunming and Shanghai, employing nearly 400 R&D personnel[41]. - The company has established a robust internal R&D management system to enhance the development of medical devices and skin health research[115]. - The company is focusing on the industrialization of Yunnan specialty plants for functional cosmetics, functional foods, and medical devices, aiming to enhance brand influence and core competitiveness[86]. - The company has ongoing projects in functional cosmetics, focusing on innovative formulations and high-efficiency products tailored for sensitive skin, with all projects progressing as planned[83]. Product Development and Sales - New product launches in 2023 are expected to contribute an additional RMB 200 million in revenue, focusing on skincare and health products[8]. - The company launched 75 new products during the reporting period, including various skincare and functional food items, focusing on innovative raw materials derived from Yunnan specialty plants[54]. - The skincare products accounted for 91.18% of the main business revenue, totaling CNY 455,715.58 million, with an average selling price of CNY 42.98, down from CNY 49.80 in the previous year[59]. - The online sales channel has seen a 30% increase in revenue, reflecting a shift in consumer purchasing behavior[8]. - The online sales channel contributed CNY 402,755.54 million, with a 23.73% increase compared to the previous year, where third-party platforms accounted for 87.54% of online sales[60]. Corporate Governance - The company has established a complete independent financial accounting system, ensuring financial independence from controlling shareholders[131]. - The company has implemented a revised independent director system to enhance decision-making and protect minority investors' rights[126]. - The company has a well-defined governance structure, including a board of directors, supervisory board, and general manager, functioning independently from controlling shareholders[133]. - The board of directors consists of nine members, including three independent directors, ensuring a diverse governance structure[140]. - The company emphasizes its commitment to corporate governance and compliance with relevant regulations[139]. Shareholder and Dividend Policies - The company plans to distribute a cash dividend of 8.00 CNY per 10 shares to all shareholders, based on a total of 423,600,000 shares[2]. - The cash dividend for 2022 was set at RMB 8.00 per 10 shares, amounting to a total cash dividend of RMB 338.88 million, which represents 100% of the total profit distribution[168]. - The company has established a profit distribution policy that emphasizes reasonable returns to shareholders, maintaining continuity and stability, with a minimum cumulative distribution of 30% of the average distributable profit over the last three years[198]. Environmental and Social Responsibility - The company strictly adheres to environmental protection laws and is not classified as a key pollutant discharge unit by environmental authorities[177]. - The company has implemented measures to reduce carbon emissions, with specific details available in the 2022 ESG report[180]. - The company is committed to fulfilling social responsibilities, including poverty alleviation and rural revitalization efforts, as detailed in the 2022 ESG report[179]. Employee and Management Practices - The total number of employees at the end of the reporting period was 3,053, including 2,131 marketing personnel and 225 production personnel[161]. - The company has implemented training programs, including the "Little Wolf Plan" for graduates and the "Apollo Plan" for mid-level management, to enhance employee skills and management capabilities[164]. - The company has established a competitive and sustainable compensation system based on market conditions and strategic development plans[163]. Risks and Challenges - The company faces risks from intensified competition in the cosmetics industry, particularly from international brands that are increasing their online marketing efforts[117]. - Seasonal fluctuations in sales revenue are significant, with major promotional events like "6·18" and "Double 11" leading to spikes in sales during the second and fourth quarters[119].

证券代码：300957 证券简称：贝泰妮 公告编号：2023-013 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）已于 2023 年 3 月 30 日在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报 告》。 为便于广大投资者进一步了解公司 2022 全年的经营情况，公司定于 2023 年 4 月 10 日（星期一）15:00 至 16:00 时举行 2022 年度业绩说明会。本次网上业 绩说明会将以网络直播的形式进行，投资者可进入全景网直播页面参与互动交 流。投资者可以在 2023 年 4 月 9 日（星期日）15:00 前，以提问的形式将关注 的问题进行提交。公司将对征集到的问题进行整理，于 2022 年度业绩说明会上 就投资者重点关注的部分问题进行回复。现将有关事项公告如下： 网上直播网址：全景网（https://rs.p5w.net） 网络提问方式： 出席本次网上业绩说明会的人员有：董事长、总经理 GUO ZHENYU（郭振 宇）先生，副总经理、财务总监、董事会秘书王龙先生，独立董事李宁先生。 欢迎广大投资者积极参与！ 特此公告。 云南贝泰妮生物科 ...